Dr Michelle Fraser, Managing Director & CEO, Reproductive Health Science

Dr Michelle Fraser is the Managing Director and CEO of publicly listed Adelaide biotechnology company Reproductive Health Science Ltd (ASX:RHS). RHS is a developer of advanced single cell genomic technologies focussed on improving health and research outcomes.

Michelle joined RHS as the inaugural CEO in September 2007 and became a member of the RHS Board in May 2012. In this role, Michelle has led the company from initial Venture Capital investment through to ASX listing in April 2014. During this time, RHS has developed and launched two kits for the genetic analysis of single cells and particularly for the determination of chromosomal content in biopsies from embryos to assist in the selection of suitable embryos for IVF transfer. The Company sells these products directly and through distributors in Israel, Russia, South Africa, China, India, UAE, Turkey and Iran.

Prior to her role at RHS, Michelle was CEO of two biotechnology start-up companies, Viswa Biotechnology Pty Ltd and BenEphex Biotechnologies Pty Ltd and was a Business Development Manager at BioInnovationSA, a South Australian State Government initiative established to assist the commercialisation of biotechnology advances in SA.

Michelle has a PhD in molecular biology, a Graduate Diploma in Science and Technology Commercialisation and is an Australian Institute of Company Directors graduate.

